Medical Cannabis for Crohn\'s Disease in the UK

Crohn's disease is a form of inflammatory bowel disease (IBD) that can cause debilitating abdominal pain, diarrhoea, and fatigue. For patients whose symptoms are not adequately managed by conventional treatments, cannabis-based medicines may be considered by a specialist as a supplementary option for symptom management.

What is Crohn's Disease?

Crohn's disease is a chronic inflammatory condition that can affect any part of the gastrointestinal tract from the mouth to the anus, though it most commonly involves the small intestine and the beginning of the large bowel (the terminal ileum and ascending colon). Unlike ulcerative colitis, the other principal form of IBD, Crohn's disease is transmural — it can affect all layers of the bowel wall — and its distribution is typically patchy rather than continuous.

Symptoms vary considerably between individuals but commonly include persistent diarrhoea (which may contain blood or mucus), cramping abdominal pain, significant fatigue, unintentional weight loss, and urgency. Crohn's disease may also cause extra-intestinal manifestations including joint pain, skin conditions, and eye inflammation. Periods of active disease (flares) alternate with periods of remission. In the UK, Crohn's disease is diagnosed and managed primarily by gastroenterologists and IBD specialist nurses.

It is important to distinguish Crohn's disease from irritable bowel syndrome (IBS). IBS is a functional gastrointestinal disorder — there is no underlying intestinal inflammation — and it is managed quite differently. Patients with IBS do not have the same clinical evidence base for cannabis prescribing as those with confirmed inflammatory bowel disease.

Conventional treatments for Crohn's disease include aminosalicylates (mesalazine), corticosteroids for acute flares, immunosuppressants (azathioprine, methotrexate), and biologic therapies (anti-TNF agents such as adalimumab and infliximab, as well as vedolizumab and ustekinumab). Despite this extensive therapeutic landscape, a proportion of patients continue to experience active symptoms, steroid dependence, or significant impairment in quality of life.

Medical Cannabis and Crohn's Disease — What Does the Evidence Say?

The gastrointestinal tract is richly endowed with cannabinoid receptors. CB1 receptors are expressed throughout the enteric nervous system, and CB2 receptors are found on immune cells within the gut mucosa. This provides a clear biological rationale for cannabinoid modulation of gastrointestinal function — including pain perception, gut motility, and intestinal inflammation.

Clinical research in Crohn's disease has produced mixed results. Several randomised controlled trials have evaluated cannabis in active Crohn's disease: while they have generally not demonstrated significant induction of remission compared to placebo in objective inflammatory endpoints, patients receiving cannabis-based medicines have consistently reported improvements in subjective symptoms — including abdominal pain, nausea, appetite, and overall quality of life — alongside reductions in steroid use in some cases. A number of observational studies report high rates of patient-reported benefit in IBD populations.

UK specialists considering cannabis prescribing for Crohn's disease therefore focus primarily on symptom management — particularly pain, nausea, appetite, and sleep disruption — rather than expecting cannabis-based medicines to induce mucosal remission or replace established IBD therapy.

Who Qualifies for a Medical Cannabis Prescription for Crohn's Disease?

• Confirmed IBD diagnosis: A gastroenterologist-confirmed diagnosis of Crohn's disease, supported by endoscopic, histological, and/or imaging findings.
• Ongoing symptomatic burden: Persistent abdominal pain, nausea, appetite loss, or fatigue that significantly impairs quality of life despite current IBD management.
• Prior conventional treatment: Appropriate standard IBD treatments tried — at least two agents appropriate for your disease stage and pattern — without achieving adequate symptom control.
• Ongoing gastroenterology involvement: Patients should remain under gastroenterology care for disease monitoring and disease-modifying treatment. Cannabis-based medicines are considered supplementary to IBD management, not a replacement.
• UK residency and adult age.

What to Expect from a Medical Cannabis Consultation for Crohn's Disease

A consultation will cover your GI history in detail: disease location, duration, current disease activity, previous surgeries, current medications, and the specific symptoms causing the most significant impairment. The prescribing specialist will review potential interactions between cannabis-based medicines and your IBD medications — including immunosuppressants and biologics. Products most commonly considered for IBD-related symptom management include CBD-dominant or balanced CBD:THC oils taken orally. THC-containing products may be considered for pain and appetite where clinically indicated. Vaporised products are generally not preferred for GI conditions where oral dosing offers a more targeted delivery route.

How Much Does Medical Cannabis Cost for Crohn's Disease in the UK?

• Initial consultation: £79 to £200 at a private cannabis clinic.
• Monthly medication: £100 to £350 per month depending on product and dose.
• Follow-up appointments: £50 to £100 per session, typically every one to three months.

See how to get a medical cannabis prescription for a step-by-step guide to the process, and UK medical cannabis clinics for a comparison of private prescribers.

Frequently Asked Questions — Medical Cannabis for Crohn's Disease UK

Can medical cannabis put Crohn's disease into remission?

Clinical trials have not demonstrated that cannabis-based medicines reliably induce mucosal remission in Crohn's disease. The primary role of cannabis prescribing in IBD is symptom management — improving pain, nausea, appetite, and quality of life — rather than replacing disease-modifying therapy.

I have IBS, not Crohn's — does that qualify?

IBS and Crohn's disease are distinct conditions. IBS is a functional disorder without intestinal inflammation. The clinical evidence base for cannabis-based medicines is considerably stronger in IBD (Crohn's or ulcerative colitis) than in IBS. A gastroenterologist should confirm your diagnosis before a cannabis consultation.

Will cannabis-based medicines interact with my biologic treatment?

Your prescribing specialist must be aware of your full medication list. Clinically significant interactions between cannabinoids and anti-TNF biologics are not well characterised, but immunosuppression and liver enzyme effects require careful assessment.

Can I use medical cannabis during a Crohn's flare?

This depends on the severity of the flare and your current treatment. Your prescribing specialist and gastroenterologist should communicate directly during active disease exacerbations to ensure safe and coordinated management.

Does smoking cannabis harm the gut in Crohn's disease?

Combusted cannabis (smoking) is not a medically acceptable delivery method and carries significant respiratory risks. Cannabis-based medicines are prescribed as pharmaceutical-grade vaporised flower (using a medical vaporiser), oils, or other formulations — not smoked products.